These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37129721)

  • 1. Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
    Guan R; Mei J; Lin W; Deng M; Li S; Guo R
    Hepatol Int; 2023 Oct; 17(5):1279-1288. PubMed ID: 37129721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
    Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Kaibori M; Iijima H; Hiasa Y; Kumada T;
    Hepatol Int; 2022 Oct; 16(5):1150-1160. PubMed ID: 35749019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
    Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
    BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy.
    Hu ZX; Xu XY; Wang Z; Huang JT; Li WC; Zhang S; Shen J; Zhong BY; Zhu XL
    J Hepatocell Carcinoma; 2023; 10():2073-2082. PubMed ID: 38022730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis.
    Yang M; Pan Y; Wang W
    BMC Cancer; 2023 Mar; 23(1):236. PubMed ID: 36915049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
    J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy.
    Yang Y; Li L; Xu Y; Ouyang J; Zhou Y; Ye F; Huang Z; Zhang W; Zhou A; Zhao X; Cai J; Wang Y; Zhou J; Zhao H
    Radiol Med; 2024 Feb; 129(2):188-201. PubMed ID: 38180570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy.
    Hsu WF; Lai HC; Chen CK; Wang HW; Chuang PH; Tsai MH; Chen SH; Chu CS; Su WP; Chou JW; Kao JT; Chen HY; Chuang SC; Tsai TY; Hsiao WD; Huang GT; Peng CY
    Am J Cancer Res; 2023; 13(2):654-668. PubMed ID: 36895987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
    Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.
    Ouyang J; Yang Y; Zhou Y; Ye F; Wang Z; Li Q; Xu Y; Li L; Zhao X; Zhang W; Zhou A; Huang Z; Wang Y; Cai J; Zhao H; Zhou J
    Hepatol Int; 2023 Dec; 17(6):1519-1531. PubMed ID: 37707759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Hatanaka T; Tani J; Takaguchi K; Atsukawa M; Itobayashi E; Nishimura T; Tsuji K; Tajiri K; Ishikawa T; Yasuda S; Toyoda H; Fukunishi S; Ogawa C; Kakizaki S; Shimada N; Naganuma A; Kawata K; Kosaka H; Kuroda H; Matono T; Yata Y; Ochi H; Tada F; Nouso K; Morishita A; Itokawa N; Okubo T; Arai T; Tsutsui A; Nagano T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2042. PubMed ID: 38577725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
    Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
    Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study.
    Yao J; Zhu X; Wu Z; Wei Q; Cai Y; Zheng Y; Hu X; Hu H; Zhang X; Pan H; Zhong X; Han W
    Cancer Med; 2022 Oct; 11(19):3612-3622. PubMed ID: 35403359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    Ueno M; Takeda H; Takai A; Morimura H; Nishijima N; Iwamoto S; Okuyama S; Umeda M; Seta T; Ikeda A; Goto T; Miyamoto S; Kayahara T; Uenoyama Y; Matsumura K; Nakano S; Mishima M; Inuzuka T; Eso Y; Takahashi K; Marusawa H; Osaki Y; Hatano E; Seno H
    J Gastroenterol; 2024 Dec; 59(12):1107-1118. PubMed ID: 39289234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
    Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
    Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
    [No Abstract]   [Full Text] [Related]  

  • 17. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.
    Campani C; Bamba-Funck J; Campion B; Sidali S; Blaise L; Ganne-Carrié N; Demory A; Sutter O; Larrey E; Evain M; Ghannouchi H; Wagner M; Marra F; Sutton A; Allaire M; Nault JC
    Liver Int; 2023 Mar; 43(3):708-717. PubMed ID: 36444741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients.
    Mao M; Wang X; Sheng H; Liu Y; Zhang L; Dai S; Chi PD
    BMC Cancer; 2018 Nov; 18(1):1178. PubMed ID: 30486825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of C-reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
    Kaneko S; Asahina Y; Murakawa M; Ueyama S; Maeyashiki C; Watanabe H; Kusano-Kitazume A; Sato A; Uchidate K; Asakawa T; Watanabe S; Iizuka Y; Shibata I; Oooka S; Karakama Y; Fujii T; Watabe T; Akahoshi K; Tanabe M; Inada K; Mochida T; Watakabe K; Shimizu T; Tsuchiya J; Miyoshi M; Kitahata-Kawai F; Nitta S; Nakagawa M; Kakinuma S; Okamoto R;
    Hepatol Res; 2024 Jun; 54(6):562-574. PubMed ID: 38133587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.
    Zhang Y; Lu L; He Z; Xu Z; Xiang Z; Nie RC; Lin W; Chen W; Zhou J; Yin Y; Xie J; Zhang Y; Zheng X; Zhu T; Cai X; Li P; Chao X; Cai MY
    Front Immunol; 2022; 13():808101. PubMed ID: 35185894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.